report an adverse event or product quality complaint

Pharmacovigilance (PV) is defined by the World Health Organisation (WHO) as “the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem.”

The aims of pharmacovigilance are:

  • to enhance patient care and patient safety in relation to the use of medicines
  • to support public health programs by providing reliable, balanced information for the effective assessment of the risk-benefit profile of medicines


The WHO established its Programme for International Drug Monitoring in response to the thalidomide disaster detected in 1961. In close collaboration with the WHO “Collaborating Centre for International Drug Monitoring”, located in Swedish Uppsala, the WHO promotes PV at the country level.

At the end of 2010, 134 countries were part of the WHO PV program. Dafra Pharma has elaborated a pharmacovigilance system compliant to the current European guidelines with the aim to protect the health of our patients. By investigating the side effects, drug interactions and other drug related problems, Dafra Pharma contributes to global healthcare.
Adverse Events (AE) can be reported here, an AE is any undesirable experience associated with the use of a medical product in a patient.
When you want to report an AE, you need to provide us with the following information.

Patient info
Reporter's details

Notice of Trademark Infringement

Dear valued partners, customers and Dafra representatives,

It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo ( In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.

Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.

We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.

We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.

As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.

Thank you for your continued support and trust in our company.

Dafra Pharma